Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PFI-90, a selective histone demethylase (KDM3B) inhibitor, targets PAX3-FOXO1 action and demonstrates potential antitumor activity. It induces apoptosis and myogenic differentiation, leading to increased cell death.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | In stock | $ 34.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 54.00 |
Description | PFI-90, a selective histone demethylase (KDM3B) inhibitor, targets PAX3-FOXO1 action and demonstrates potential antitumor activity. It induces apoptosis and myogenic differentiation, leading to increased cell death. |
Targets&IC50 | RH30:3200nM, TC-32 cells:1113nM, RH4:812 nM, OSA-CL cells:1895nM |
In vitro | PFI-90 (3 μΜ; 24 hours) increases apoptosis in RH4 and SCMC cells[1]. |
Molecular Weight | 214.22 |
Formula | C11H10N4O |
CAS No. | 53995-62-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 20 mg/mL (93.36 mM), Sonication and heating are recommended.
DMSO: 40 mg/mL (186.72 mM)
H2O: insoluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PFI-90 53995-62-3 Chromatin/Epigenetic Others Histone Demethylase antitumor Inhibitor differentiation PAX3-FOXO1 demethylase PFI90 apoptosis histone PFI 90 myogenic inhibit inhibitor